2 results
Approved WMOCompleted
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
Approved WMOCompleted
Primary objective: To evaluate the optimum comfortable on-demand humidification doses for neuromuscular patients requiring chronic mechanical ventilation using subjective as well as objective measurements of the optimum comfort.